Nanoparticle-based cancer treatment: a look at its origins and what's next
from R&D Magazine
It has been just over two decades since the first nanoparticle-based therapy was FDA approved for the treatment of cancer. In that time, the field has grown and matured significantly, attracting the interest of an increasing number of researchers across multiple disciplines, said Piotr Grodzinski, Ph.D., the Chief of Nanodelivery Systems and Devices Branch at the Cancer Imaging Program of the National Cancer Institute (NCI).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063